Non-small Cell Lung Cancer Metastatic Clinical Trials

19 recruitingLast updated: June 17, 2026

There are 19 actively recruiting non-small cell lung cancer metastatic clinical trials across 29 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Guangzhou, Guangdong, China, Marseille, France, Basking Ridge, New Jersey, United States. Updated daily from ClinicalTrials.gov.


Non-small Cell Lung Cancer Metastatic Trials at a Glance

19 actively recruiting trials for non-small cell lung cancer metastatic are listed on ClinicalTrialsFinder across 6 cities in 29 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Guangzhou, Marseille, and Basking Ridge. Lead sponsors running non-small cell lung cancer metastatic studies include Memorial Sloan Kettering Cancer Center, Sun Yat-sen University, and Fondazione IRCCS Policlinico San Matteo di Pavia.

Browse non-small cell lung cancer metastatic trials by phase

Treatments under study

About Non-small Cell Lung Cancer Metastatic Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer Metastatic? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Not Applicable

Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic
University Medical Center Groningen100 enrolled3 locationsNCT05864794
Recruiting
Phase 2

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung CancerNSCLCNon-small Cell Lung Cancer Metastatic+2 more
Memorial Sloan Kettering Cancer Center68 enrolled9 locationsNCT05657873
Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNSCLC+6 more
GFPC Investigation100 enrolled16 locationsNCT07563205
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled305 locationsNCT07144280
Recruiting
Phase 2

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Non-small Cell Lung Cancer Metastatic
Memorial Sloan Kettering Cancer Center56 enrolled8 locationsNCT06741085
Recruiting
Phase 2

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Non-small Cell Lung Cancer Metastatic
Samsung Medical Center47 enrolled1 locationNCT06106802
Recruiting
Phase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IV+2 more
University of California, Davis56 enrolled1 locationNCT07250477
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Not Applicable

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

Non-small Cell Lung Cancer Metastatic
Zealand University Hospital350 enrolled5 locationsNCT05889247
Recruiting
Phase 1

A Phase Ib Study of GC101 in NSCLC

Non-small Cell Lung CancerNon-small Cell Lung Cancer Metastatic
Shanghai Juncell Therapeutics20 enrolled1 locationNCT06473961
Recruiting
Phase 2

PALACE: Cemiplimab Trial According to ctDNA Levels

Non-small Cell Lung Cancer MetastaticThoracic NeoplasmsStage IV Non-Small Cell Lung Cancer+3 more
Fundación GECP63 enrolled20 locationsNCT06917573
Recruiting

First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)

Non-small Cell Lung Cancer Metastatic
Fondazione IRCCS Policlinico San Matteo di Pavia300 enrolled1 locationNCT07190677
Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Non-small Cell Lung Cancer MetastaticSmall Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)+3 more
AIO-Studien-gGmbH12,400 enrolled1 locationNCT02622581
Recruiting
Phase 2

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Non-small Cell Lung Cancer Metastatic
Sun Yat-sen University30 enrolled1 locationNCT06812871
Recruiting
Phase 2

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University23 enrolled1 locationNCT06517953
Recruiting
Phase 3

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Non-small Cell Lung Cancer Metastatic
Laboratorio Elea Phoenix S.A.174 enrolled1 locationNCT05668650
Recruiting
Phase 2

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Non-small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano45 enrolled9 locationsNCT06378892
Recruiting
Phase 1

An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Non-small Cell Lung Cancer Metastatic
Lu Shun35 enrolled1 locationNCT06083870
Recruiting
Phase 3

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic
Shanghai Cancer Hospital, China300 enrolled1 locationNCT05800223